Martin Welschof
Andres McAllister
Ashley Robinson
Martin Welschof
Ph.D. (Dr.rer.nat.) in recombinant antibody technology. Employed since 2018. He did his postdoctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology both in Heidelberg, Germany. Martin has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, CEO of Affitech (Nasdaq Copenhagen) and CEO of Opsona Therapeutics, Dublin, Ireland. Member of the Board of Anocca, APIM Therapeutics AS and Nextera AS. Born 1961.
Shareholding: 22,400
Conditional Employee Options: Option program 2019/2025: 1,108,095 Option program 2022/2024: 54,000 Option program 2023/2025: 34,000 Option program 2024/2026: 16,000
Andres McAllister
Doctor in Medicine and Surgery from the Universidad del Rosario (Bogotá), and holds a PhD from the Institut Pasteur/Université Paris 7. Employed since 2017. He has performed academic work at the Pasteur Institute and the University of California, San Francisco on cancer immunotherapy. Andres joins BioInvent from a position as Chief Scientific Officer at Debiopharm, and has previously held senior roles at IDM and BioMérieux/ Pierre Fabre. Born 1956.
Shareholding: 3,009
Conditional Employee Options: Option program 2019/2025: 772,776 Option program 2022/2024: 27,000 Option program 2023/2025: 17,000 Option program 2024/2026: 8,000
Ashley Robinson
Has 25 years’ of experience in capital markets and corporate strategy experience. Employed since 2024. Before joining BioInvent, he served as Managing Director at LifeSci Advisors, where he established an office in Boston, advising key clients in the healthcare sector. Prior roles have been healthcare product specialist and sector head at Guggenheim Securities, Managing Director and Senior Partner at Leerink Partners, Vice President of ECM at Lehman Brothers. Born 1977.
Shareholding: -
Conditional employee options: -
Björn Frendéus
Kristoffer Rudenholm Hansson
Marie Moores
Björn Frendéus
Doctor of Immunology. Employed since 2001. Frequent publisher in leading scientific immunology journals, and speaker and chair at international Immuno-oncology conferences. Inventor on more than 150 patents and patent applications. Visiting Professor at University of Southampton. Born 1973.
Shareholding: 23,089 (own and affiliated holdings)
Conditional Employee Options: Option program 2019/2025: 664,857 Option program 2022/2024: 27,000 Option program 2023/2025: 17,000 Option program 2024/2026: 8,000
Kristoffer Rudenholm Hansson
Master of Science in Chemical engineering. Employed since 2016 and is responsible for process development and production of antibodies for clinical studies. He has 25 years of experience from managing manufacturing of antibodies and other proteins for clinical use. Kristoffer has held numerous positions within CMC Biologics A/S (now AGC Biologics), DAKO A/S and Symphogen A/S. Born 1974.
Shareholding: 22,303 (whereof 7,177 in endowment insurance)
Conditional Employee Options: : Option program 2019/2025: 353,259 Option program 2022/2024: 27,000 Option program 2023/2025: 17,000 Option program 2024/2026: 8,000
Marie Moores
Over 28 years’ experience of transforming international organizations, with expertise in regulatory affairs and building businesses focusing on drug development. Employed 2022. Chair of the board of Aidee Health and a jury panelist and business coach of the European Innovation Council (EIC) which supports innovation, from early-stage research to startups and scaleups with a special focus on breakthrough, market-creating and deep-tech innovations. Former Executive Vice President, International Operations & Early Development at the Norwegian company LINK Medical Research. She previously spent more than 20 years with Theradex Oncology as Director, Clinical and Regulatory Operations for Europe. Born 1968.
Shareholding: -
Conditional Employee Options: Option program 2022/2024: 27,000 Option program 2023/2025: 17,000 Option program 2024/2026: 8,000
Stefan Ericsson
Sylvie Ryckebusch
Ingunn Munch Lindvig
Stefan Ericsson
MBA, Lund University. Employed since 1998. Chief Financial Officer since 2016 and has previously served as Director Business Control. Previous experience from the Swedish Tax Agency and as auditor at PricewaterhouseCoopers. Born 1963.
Shareholding: 8,000
Conditional Employee Options: Option program 2019/2025: 347,055 Option program 2022/2024: 27,000 Option program 2023/2025: 17,000 Option program 2024/2026: 8,000
Sylvie Ryckebusch
PhD in neurobiology from the California Institute of Technology and BSc degrees in physics and mathematics from the University of Maryland, US. Employed since 2022. 25 years of experience in business development, alliance management, and corporate strategy. Sylvie has served in key positions at Serono, Merck KGaA, numerous biotechs, and Index Ventures as well as McKinsey & Company and the Harvard Business School. Born 1965.
Shareholding: 22,870 (own and affiliated holdings)
Conditional Employee options: -
Ingunn Munch Lindvig
PhD in Biology from the University of Oslo. Employed since 2023. Experienced regulatory affairs leader who has worked across all stages of product development and has hands-on experience of the US and EU regulatory systems. Previously Vice President and Head of Regulatory Affairs at Circio, Head of Regulatory Affairs at Nordic Nanovector and also held senior regulatory positions at Photocure and Nycomed/ GE Healthcare. Born 1965.
Shareholding: -
Conditional employee options: Option program 2023/2025: 12,741 Option program 2024/2026: 8,000
Leonard Kruimer
Natalie Berner
Elin Birgersson
Leonard Kruimer
Chairman of the Board since 2018. Member of the Remuneration Committee and the Audit Committee. MBA, CPA. He served as a Board Member in BioInvent between 2016– 2017. He has held senior executive and board positions at European and US based biotech companies. He held senior executive positions at royal Boskalis NV, GE Capital and Continental Canada Company and has been a consultant with McKinsey and an auditor with Price Waterhouse New York. Born 1958.
Other board appointments: Board member in Zealand Pharma A/S, Basilea International AG and Pharming Group NV. Director in AI Global Investments (Netherlands ) PCC Ltd.
Shareholding: 27,538
Natalie Berner
Member of the Board since 2022.
BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University. Previous Research Associate at the New York University School of Medicine. Currently Managing Director, Therapeutics at Redmile Group, LLC. Born 1990.
Other board appointments: Redx Pharma Plc and Sensorion SA.
Shareholding: -
Elin Birgersson
Member of the Board since 2023.
M.Sc. in Chemical biology. Elin has worked at the university (KTH) and pharma and biotech industry since 2012 and has experience in antibody discovery and high-throughput analysis. Born 1985.
Other board appointments: -
Shareholding: 92 (affiliated holdings)
Conditional Employee Options: Option program 2022/2024: 3,099; option program 2023/2025: 1,266; option program 2024/2026: 498
Kristoffer Bissessar
Thomas Hecht
Laura Lassouw-Polman
Kristoffer Bissessar
Member of the Board since 2020.
Broad experience from the financial industry, operative in banking and finance between 1989 – 2012, with experience from asset management, institutional equity sales and investment banking. Previously held senior positions at Svenska Handelsbanken AB, Deutsche Bank AG and Nordea Bank AB and served as board member of the Swedish Securities Dealers Association. Board member of BioInvent during 2018-2019. Born 1968.
Other board appointments: Xbrane Biopharma AB.
Shareholding: 29,000
Thomas Hecht
Member of the Board since 2020.
Doctor of Medicine. Previously experience as Vice President Marketing at Amgen Europe and has held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, Thomas Hecht was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation at the University of Freiburg, Germany. Currently Managing Partner at HHC Healthcare Consulting. Born 1951.
Other board appointments: Chairman of the board of Affimed N.V.
Shareholding: -
Laura Lassouw-Polman
Member of the Board since 2024.
Chief Operating Officer at Sairopa BV, the Netherlands, since 2021. Laura has a Master of Science in Health Sciences from Maastricht University and has previously worked at several companies in the pharmaceutical sector, including the AstraZeneca Group (Acerta Pharma), PPD and ICON Clinical Research, conducting clinical studies for cancer treatment in senior positions. Born 1979.
Other board appointments: -
Shareholding: -
Nanna Lüneborg
Tomas Wall
Bernd Seizinger
Nanna Lüneborg
Member of the Board since 2022.
. PhD in Neuroscience from University College London, MBA from the University of Cambridge and a BA in Physiology and Psychology from the University of Oxford. Currently General Partner at Forbion. Prior experience with Apposite Capital and Novo Holdings. Nanna has previously served on the Board of Directors of publicly traded and privately held companies, including Inversago Pharma (acquired by Novo Nordisk), Lava Therapeutics (LVTX), Numab (asset spin-out Yellow Jersey acquired by J&J), ReViral (acquired by Pfizer), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva (IVA), Orphazyme (ORPHA), NodThera (private), MinervaX (private), and Stargazer (private). Born 1975.
Other board appointments: Board member in Capstan, F2G and Noema Pharma, board observer in Numab Therapeutics.
Shareholding: -
Tomas Wall
Member of the Board since 2025.
Tomas has worked in IT Management since 2007 at companies in manufacturing, medical distribution, and pharma. Born in 1981.
Other board appointments: -
Shareholding:1,240
Conditional Employee Options: Option program 2023/2025: 3,116. Option program 2024/2026: 1,466.
Bernd Seizinger
Member of the Board since 2018.
Doctor of Medicine and Doctor of Neurobiology. Previous experience as CEO and President of GPC Biotech, Executive Vice President and Chief Scientific Officer at Genome Therapeutics Corporation and Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances, both at Bristol-Myers Squibb. Senior faculty positions at Harvard Medical School, Massachusetts General Hospital, and Princeton University. Born 1956.
Other board appointments: Board member and chairman of multiple public and private biotech companies in the United States, Europe, and Canada, including Oxford BioTherapeutics, CryptoMedix Inc., Oncolytics Biotech Inc., Aprea AB, and Aptose Inc. Advisory board member/Senior Advisor to Biotech Venture Capital Funds such as Pureos BioVentures and Hadean Ventures.
Shareholding: 66,000